IPO

Zoom Shares Surge on Anthropic IPO Filing, Highlighting $1.27B AI Bet

Zoom shares rose 11% as Anthropic's confidential IPO filing brought attention to Zoom's $1.27 billion investment in the AI firm. Zoom also introduced ZoomMate, a $20/month AI assistant.

Michael Okonkwo · · · 3 min read · 2 views
Zoom Shares Surge on Anthropic IPO Filing, Highlighting $1.27B AI Bet
Mentioned in this article
ZM $111.62 +9.87%

Zoom Communications (ZM) saw its shares climb nearly 11% in Monday trading, reaching an intraday high of $114.56, after Anthropic confidentially filed for an initial public offering. The filing cast a spotlight on Zoom's $1.27 billion preferred stock stake in the artificial intelligence company, which now represents a significant asset on Zoom's balance sheet.

The stock ended the session up about 10.7%, boosting Zoom's market capitalization to roughly $33.8 billion. Investors have increasingly viewed Zoom as more than just a slow-growth video conferencing provider, with its Anthropic holdings offering a potential catalyst for future valuation re-rating.

Anthropic disclosed Monday that it had confidentially submitted a draft Form S-1 to the Securities and Exchange Commission for a potential stock listing. The company has not yet determined the number of shares or a price range, and cautioned that the IPO's timing and completion depend on market conditions and other factors.

Zoom's latest quarterly filing revealed it added $46 million to its Anthropic preferred stock holdings during the period ending April 30, bringing the carrying value to $1.2669 billion. The company also invested $99.7 million in other private AI firms during the same period, underscoring its commitment to the sector.

In a separate announcement Monday, Zoom launched ZoomMate, a new agentic AI work surface designed to automate meeting tasks. Unlike traditional AI tools that merely respond to queries, ZoomMate can search, plan, and act across different software platforms. The tool connects to Salesforce, Jira, Slack, ServiceNow, and Google and Microsoft products. Pricing starts at $20 per user per month, and the service is available across North America.

Russell Dicker, Zoom's chief product officer, said ZoomMate bridges the gap between 'what was decided' in meetings and 'what needs to happen next.' Melody Brue, vice president and principal analyst at Moor Insights & Strategy, noted the shift away from 'isolated AI helpers' toward systems that link decisions, data, and workflows.

Wall Street hovered near record highs, with technology stocks leading the charge. Gains in the sector helped offset concerns about rising oil prices and escalating U.S.-Iran tensions, according to Reuters.

The Anthropic filing keeps Zoom at the center of the broader AI investment narrative. D.A. Davidson analyst Gil Luria told Reuters that OpenAI and Anthropic are 'in a race to go public before capital runs out,' noting that being first could help as SpaceX, OpenAI, and Anthropic compete for investor capital.

Zoom's core business continues to show stability. In May, the company reported fiscal first-quarter 2027 revenue of $1.239 billion, up 5.5% year-over-year, with enterprise revenue rising 7.2%. CEO Eric Yuan said customers are increasingly using Zoom as an 'AI-first system of action.' The board also authorized an additional $1 billion for share buybacks.

However, competition remains intense. Zoom's filings cite Microsoft 365 with Teams, Google Workspace with Meet, and Cisco Webex as key rivals. The launch of ZoomMate represents an effort to keep Zoom central to daily work, even as bundled competitors expand into meetings, chat, and productivity tools. The Anthropic investment, while promising, carries risks: private-company valuations are inherently volatile, and any payoff depends on a liquidity event such as an IPO or acquisition. If Anthropic's IPO faces delays, lower pricing, or a weak market, investor attention could quickly shift back to Zoom's core revenue challenges and competitive pressures.

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Market data may be delayed. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Related Articles

View All →